ArticlePharmaceuticals (Basel, Switzerland)2025

HDAC/σ1R Dual-Ligand as a Targeted Melanoma Therapeutic.

Claudia Giovanna Leotta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.